Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.
Also called NCT02988245
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 1,000 participants
- Sponsor
- Registry
-
NCT02988245
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT02988245. Randomized; single masking; primary purpose treatment. Start 2022-06 (anticipated); primary completion 2023-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension
- Acronym
- PGEN for HTN
- Condition
- Hypertension
- Intervention (Drug)
- Geneticure Panel for HTN therapy
- Intervention (Drug)
- JNC-8
- Lead sponsor
- Geneticure, LLC
- Collaborator
- Fairview Health Services
- Collaborator
- University of Minnesota
Record details
- Record id
cardio:ct-nct02988245- Content hash
908c43d63abdc1267c2c7da61fc551a6ed39c8917b4bdb02c49ce9682f7bdeb7